Karyopharm Therapeutics Inc (NASDAQ: KPTI) is 5.87% higher on its value in year-to-date trading and has touched a low of $0.58 and a high of $1.95 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The KPTI stock was last observed hovering at around $0.77 in the last trading session, with the day’s loss setting it -0.05%.
Currently trading at $0.72, the stock is 2.57% and -9.02% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.41 million and changing -6.92% at the moment leaves the stock -22.09% off its SMA200. KPTI registered -22.20% loss for a year compared to 6-month loss of -17.38%. The firm has a 50-day simple moving average (SMA 50) of $0.78924 and a 200-day simple moving average (SMA200) of $0.922395.
The stock witnessed a -6.80% gain in the last 1 month and extending the period to 3 months gives it a -15.07%, and is 5.87% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.97% over the week and 8.65% over the month.
Karyopharm Therapeutics Inc (KPTI) has around 325 employees, a market worth around $90.36M and $148.44M in sales. Profit margin for the company is -58.93%. Distance from 52-week low is 23.26% and -63.28% from its 52-week high. The company has generated returns on investments over the last 12 months (-282.69%).
The EPS is expected to grow by 43.09% this year
111.0 institutions hold shares in Karyopharm Therapeutics Inc (KPTI), with institutional investors hold 51.43% of the company’s shares. The shares outstanding are 125.30M, and float is at 115.36M with Short Float at 17.16%. Institutions hold 48.24% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 7.65 million shares valued at $6.64 million. The investor’s holdings represent 6.6299 of the KPTI Shares outstanding. As of 2024-06-30, the second largest holder is PALO ALTO INVESTORS LP with 5.1 million shares valued at $4.43 million to account for 4.4192 of the shares outstanding. The other top investors are EVERSEPT PARTNERS, LP which holds 4.99 million shares representing 4.3196 and valued at over $4.33 million, while ADAGE CAPITAL PARTNERS GP, L.L.C. holds 3.7416 of the shares totaling 4.32 million with a market value of $3.75 million.
Karyopharm Therapeutics Inc (KPTI) Insider Activity
The most recent transaction is an insider sale by Paulson Richard A., the company’s President and CEO. SEC filings show that Paulson Richard A. sold 4,055 shares of the company’s common stock on Jan 06 ’25 at a price of $0.78 per share for a total of $3175.0. Following the sale, the insider now owns 1.12 million shares.
Karyopharm Therapeutics Inc disclosed in a document filed with the SEC on Dec 04 ’24 that Paulson Richard A. (President and CEO) sold a total of 3,620 shares of the company’s common stock. The trade occurred on Dec 04 ’24 and was made at $0.81 per share for $2932.0. Following the transaction, the insider now directly holds 1.13 million shares of the KPTI stock.
Still, SEC filings show that on Nov 05 ’24, Paulson Richard A. (President and CEO) disposed off 3,675 shares at an average price of $0.91 for $3346.0. The insider now directly holds 1,131,932 shares of Karyopharm Therapeutics Inc (KPTI).
